Skip to content
Molecular Immunology

Publications

2024

  1. Atomwise AIMS Program. AI is a viable alternative to high throughput screening: a 318-target study. Sci Rep. 2024;14 (1):7526. doi: 10.1038/s41598-024-54655-z. PubMed PMID:38565852 PubMed Central PMC10987645.
  2. Abraham, BG, Haikarainen, T, Vuorio, J, Girych, M, Virtanen, AT, Kurttila, A et al.. Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Sci Adv. 2024;10 (10):eadl2097. doi: 10.1126/sciadv.adl2097. PubMed PMID:38457493 PubMed Central PMC10923518.

Search PubMed

2023

  1. Arwood, ML, Liu, Y, Harkins, SK, Weinstock, DM, Yang, L, Stevenson, KE et al.. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell Chem Biol. 2023;30 (6):618-631.e12. doi: 10.1016/j.chembiol.2023.05.007. PubMed PMID:37290440 PubMed Central PMC10495080.
  2. Saarikettu, J, Lehmusvaara, S, Pesu, M, Junttila, I, Partanen, J, Sipilä, P et al.. The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression. FASEB Bioadv. 2023;5 (5):183-198. doi: 10.1096/fba.2022-00115. PubMed PMID:37151849 PubMed Central PMC10158624.
  3. Pölläniemi, A, Virtanen, A, Silvennoinen, O, Haikarainen, T. Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening. SLAS Discov. 2023;28 (4):180-187. doi: 10.1016/j.slasd.2023.05.001. PubMed PMID:37149038 .
  4. Virtanen, A, Palmroth, M, Liukkonen, S, Kurttila, A, Haikarainen, T, Isomäki, P et al.. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling. Arthritis Rheumatol. 2023;75 (11):2054-2061. doi: 10.1002/art.42547. PubMed PMID:37134144 .
  5. Virtanen, AT, Haikarainen, T, Sampathkumar, P, Palmroth, M, Liukkonen, S, Liu, J et al.. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel). 2023;16 (1):. doi: 10.3390/ph16010075. PubMed PMID:36678572 PubMed Central PMC9865020.

Search PubMed

2022

  1. Telliez, JB, Gadina, M, Ghoreschi, K, Silvennoinen, O, Spinelli, FR. Editorial: JAK inhibition in autoimmune and inflammatory diseases. Front Immunol. 2022;13 :1120281. doi: 10.3389/fimmu.2022.1120281. PubMed PMID:36643918 PubMed Central PMC9832019.
  2. Valli, A, Kuuliala, K, Virtanen, A, Kuuliala, A, Palmroth, M, Peltomaa, R et al.. Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response. Clin Exp Immunol. 2022;210 (2):141-150. doi: 10.1093/cei/uxac085. PubMed PMID:36124688 PubMed Central PMC9750823.
  3. Silvennoinen, O, Haikarainen, T, Virtanen, A. Aiming for the pocket. Nat Chem Biol. 2022;18 (12):1296-1297. doi: 10.1038/s41589-022-01120-5. PubMed PMID:36097296 .
  4. Lehmusvaara, S, Haikarainen, T, Saarikettu, J, Martinez Nieto, G, Silvennoinen, O. Inhibition of RNA Binding in SND1 Increases the Levels of miR-1-3p and Sensitizes Cancer Cells to Navitoclax. Cancers (Basel). 2022;14 (13):. doi: 10.3390/cancers14133100. PubMed PMID:35804872 PubMed Central PMC9265050.

Search PubMed

2021

  1. Palmroth, M, Kuuliala, K, Peltomaa, R, Virtanen, A, Kuuliala, A, Kurttila, A et al.. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis and Baseline Signaling Profile Associates With Treatment Response. Front Immunol. 2021;12 :738481. doi: 10.3389/fimmu.2021.738481. PubMed PMID:34630419 PubMed Central PMC8498592.
  2. Palmroth, M, Viskari, H, Seppänen, MRJ, Keskitalo, S, Virtanen, A, Varjosalo, M et al.. Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia. Pharmaceuticals (Basel). 2021;14 (8):. doi: 10.3390/ph14080797. PubMed PMID:34451894 PubMed Central PMC8402006.
  3. Raivola, J, Haikarainen, T, Abraham, BG, Silvennoinen, O. Janus Kinases in Leukemia. Cancers (Basel). 2021;13 (4):. doi: 10.3390/cancers13040800. PubMed PMID:33672930 PubMed Central PMC7918039.

Search PubMed

2020

  1. Pastore, F, Krishnan, A, Hammarén, HM, Silvennoinen, O, Yan, B, Levine, RL et al.. JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs. Blood Adv. 2020;4 (18):4554-4559. doi: 10.1182/bloodadvances.2019001283. PubMed PMID:32956452 PubMed Central PMC7509885.

Search PubMed

2019

  1. Raivola, J, Haikarainen, T, Silvennoinen, O. Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling. Cancers (Basel). 2019;12 (1):. doi: 10.3390/cancers12010078. PubMed PMID:31892268 PubMed Central PMC7016850.
  2. Gadina, M, Le, MT, Schwartz, DM, Silvennoinen, O, Nakayamada, S, Yamaoka, K et al.. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019;58 (Suppl 1):i4-i16. doi: 10.1093/rheumatology/key432. PubMed PMID:30806710 PubMed Central PMC6657570.
  3. T Virtanen, A, Haikarainen, T, Raivola, J, Silvennoinen, O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33 (1):15-32. doi: 10.1007/s40259-019-00333-w. PubMed PMID:30701418PubMed Central PMC6373396.
  4. Hammarén, HM, Virtanen, AT, Abraham, BG, Peussa, H, Hubbard, SR, Silvennoinen, O et al.. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. J Allergy Clin Immunol. 2019;143 (4):1549-1559.e6. doi: 10.1016/j.jaci.2018.07.022. PubMed PMID:30092288 PubMed Central PMC6363912.
  5. Hammarén, HM, Virtanen, AT, Raivola, J, Silvennoinen, O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118 :48-63. doi: 10.1016/j.cyto.2018.03.041. PubMed PMID:29685781 .

Search PubMed

2018

  1. Raivola, J, Hammarén, HM, Virtanen, AT, Bulleeraz, V, Ward, AC, Silvennoinen, O et al.. Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain. Front Oncol. 2018;8 :560. doi: 10.3389/fonc.2018.00560. PubMed PMID:30560087 PubMed Central PMC6287396.
  2. Hammarén, HM, Virtanen, AT, Abraham, BG, Peussa, H, Hubbard, SR, Silvennoinen, O et al.. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. J Allergy Clin Immunol. 2019;143 (4):1549-1559.e6. doi: 10.1016/j.jaci.2018.07.022. PubMed PMID:30092288 PubMed Central PMC6363912.
  3. Hammarén, HM, Virtanen, AT, Raivola, J, Silvennoinen, O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118 :48-63. doi: 10.1016/j.cyto.2018.03.041. PubMed PMID:29685781 .
  4. Ranta, N, Valli, A, Grönholm, A, Silvennoinen, O, Isomäki, P, Pesu, M et al.. Proprotein convertase enzyme FURIN is upregulated in primary Sjögren’s syndrome. Clin Exp Rheumatol. ;36 Suppl 112 (3):47-50. . PubMed PMID:29465367 .
  5. Fu, X, Zhang, C, Meng, H, Zhang, K, Shi, L, Cao, C et al.. Oncoprotein Tudor-SN is a key determinant providing survival advantage under DNA damaging stress. Cell Death Differ. 2018;25 (9):1625-1637. doi: 10.1038/s41418-018-0068-9. PubMed PMID:29459768 PubMed Central PMC6143532.

Search PubMed

2017

  1. Puleo, DE, Kucera, K, Hammarén, HM, Ungureanu, D, Newton, AS, Silvennoinen, O et al.. Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. ACS Med Chem Lett. 2017;8 (6):618-621. doi: 10.1021/acsmedchemlett.7b00153. PubMed PMID:28626521 PubMed Central PMC5467198.
  2. Saarimäki-Vire, J, Balboa, D, Russell, MA, Saarikettu, J, Kinnunen, M, Keskitalo, S et al.. An Activating STAT3 Mutation Causes Neonatal Diabetes through Premature Induction of Pancreatic Differentiation. Cell Rep. 2017;19 (2):281-294. doi: 10.1016/j.celrep.2017.03.055. PubMed PMID:28402852 .

Search PubMed

2016

  1. Pertovaara, M, Silvennoinen, O, Isomäki, P. Cytokine-induced STAT1 activation is increased in patients with primary Sjögren’s syndrome. Clin Immunol. 2016;165 :60-7. doi: 10.1016/j.clim.2016.03.010. PubMed PMID:26995659 .

Search PubMed